Stoke Therapeutics Inc.

Stoke Therapeutics Inc. is a biotechnology company focused on developing RNA-based treatments for genetic diseases. Its primary aim is to address disorders caused by a lack of protein expression due to gene dysregulation. Utilizing its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform, Stoke Therapeutics is at the forefront of creating innovative therapies that specifically increase protein production in target tissues. This approach has a profound impact on rare genetic conditions, particularly those affecting the central nervous system and the liver. One of the key programs in the company's pipeline is aimed at treating Dravet syndrome, a severe form of epilepsy. The company's work is significant in the biopharmaceutical sector, as it opens new pathways for RNA-based therapeutics, offering potential solutions for conditions that have, until now, had limited or no treatment options. By pioneering such advanced technologies, Stoke Therapeutics stands as a crucial player in the quest to transform the treatment landscape for patients with unmet medical needs.